Atopic Dermatitis Clinical Trials: 342 Active Trials, 48 Changes This Month

35 trials changed in the last 30 days: 1 stopped, 9 with notable changes, 25 with minor changes only.

Stopped

Adoring · Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Trial status changed: Active, Not Recruiting → Suspended

Sponsor's reason: As a precaution, study drug dosing is paused due to a PK finding in OG505-3104. No safety signal or change to the established safety or benefit-risk profile has been identified. The Sponsor is further investigating and assessing the data.

Organon and CoPhase 3 NCT07265479 Registry history of NCT07265479 on ClinicalTrials.gov (opens the registry)

Updated Oct 5, 2026
Notable

Of BAT6026

Primary completion pushed from Jun 1, 2026 to Dec 31, 2026

Also in this update: Study completion pushed from Jun 30, 2026 to Dec 31, 2026

Bio-Thera SolutionsPhase 1/2 NCT06094179 Registry history of NCT06094179 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Notable

FinnATOPY · Allergy, Asthma, and Atopic Eczema in Finland

Enrollment reduced: 2000000 → 1200000 participants

Also in this update: Interventions modified; Trial arms changed: 0 → 6

Tampere UniversityNot specified NCT06330974 Registry history of NCT06330974 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

GS101 Injection to Dupixent®

Recruitment opened

Jiangsu Genscend Biopharmaceutical Co., LtdPhase 3 NCT07386743 Registry history of NCT07386743 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

Equivalence of IBI3027 and Dupilumab Injection · Moderate to Severe Atopic Dermatitis

Recruitment opened

Innovent Biologics (Suzhou) Co. Ltd.Phase 3 NCT07754786 Registry history of NCT07754786 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Notable

611 · Moderate to Severe Atopic Dermatitis(AD)

Recruitment opened

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.Phase 3 NCT07767253 Registry history of NCT07767253 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Notable

Tilrek · Called Tilrekimig · Moderate-to Severe Eczema

Recruitment opened

Also in this update: Trial sites expanded: 1 → 22 locations

PfizerPhase 3 NCT07783425 Registry history of NCT07783425 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Notable

BYN-001-101 · BYN-001 in Healthy Adults and · Moderate to Severe Atopic Dermatitis

Recruitment opened

Bionyra PharmaPhase 1 NCT07746817 Registry history of NCT07746817 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Notable

PROTEGO · Retention of Vernix Caseosa in Newborns for Primary Prevention of Atopic Dermatitis

Recruitment opened

Pontificia Universidad Catolica de ChileNot applicable NCT07333378 Registry history of NCT07333378 on ClinicalTrials.gov (opens the registry)

Updated Sep 30, 2026
Notable

ENV-294 · Moderate-to-Severe Atopic Dermatitis

Enrollment increased: 60 → 105 participants

Enveda TherapeuticsPhase 2 NCT07298395 Registry history of NCT07298395 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026

Show 25 trials with minor changes only

Minor

ADsolve · See How Well Lebrikizumab Works in Adults and · Moderate Atopic Dermatitis (Eczema) and High Itch Burden

Trial completed

Eli Lilly and CompanyPhase 4 NCT07006792 Registry history of NCT07006792 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

GS101 and Dupixent® After Subcutaneous Injection

Trial completed

Jiangsu Genscend Biopharmaceutical Co., LtdPhase 1 NCT07411755 Registry history of NCT07411755 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

Clinical-Instrumental Study To Evaluate And Compare The Efficacy And Tolerability Of Two Emollients Products In Atopic Dermatitis

Trial completed

NAOS Les LaboratoiresNot applicable NCT06930365 Registry history of NCT06930365 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

EVO756 · Atopic Dermatitis

Trial completed

Evommune, Inc.Phase 2 NCT07150845 Registry history of NCT07150845 on ClinicalTrials.gov (opens the registry)

Updated Oct 2, 2026
Minor

Cohort Study Being Conducted · Atopic Dermatitis (AD)

Trial completed

Also in this update: Primary completion date changed from estimate of Jan 21, 2027 to Apr 13, 2026; Final enrollment: 12343 participants (planned 3930)

Regeneron PharmaceuticalsNot specified NCT03936335 Registry history of NCT03936335 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

FRAME · French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Enrollment closed, study ongoing

SanofiNot specified NCT06837454 Registry history of NCT06837454 on ClinicalTrials.gov (opens the registry)

Updated Sep 28, 2026
Minor

PROTYPE2 · Real-world Effectiveness Study of Long-term Treatment With Dupilumab in Participants ≥6 Years With Atopic Dermatitis

Enrollment closed, study ongoing

Also in this update: Final enrollment: 572 participants (planned 900)

SanofiNot specified NCT06039241 Registry history of NCT06039241 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

HA35-ITCH · HA35 Gel for Ultra-Rapid Skin Pruritus Relief

Completed without a posted recruiting period

Nakhia Impex LLCNot applicable NCT07580911 Registry history of NCT07580911 on ClinicalTrials.gov (opens the registry)

Updated Sep 22, 2026
Minor

Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema

Enrollment reduced: 500 → 450 participants

PfizerPhase 3 NCT06807281 Registry history of NCT06807281 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

AD · Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis

Enrollment closed, study ongoing

Daniel KaplanPhase 1 NCT06928246 Registry history of NCT06928246 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

DEPRO · Dermocosmetic Evaluation of Propolis Ointments in Atopic-Prone Dry Skin

Trial completed

Manara UniversityNot applicable NCT07618234 Registry history of NCT07618234 on ClinicalTrials.gov (opens the registry)

Updated Oct 8, 2026
Minor

MADULO · Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents · Atopic Dermatitis

Trial completed

Nantes University HospitalPhase 4 NCT05642208 Registry history of NCT05642208 on ClinicalTrials.gov (opens the registry)

Updated Sep 24, 2026
Minor

Called Tilrekimig · Moderate-to-Severe Eczema

Trial sites expanded: 3 → 21 locations

PfizerPhase 3 NCT07765888 Registry history of NCT07765888 on ClinicalTrials.gov (opens the registry)

Updated Oct 15, 2026
Minor

Psychodermatologic Educational Modules on Atopic Dermatitis Patient Outcomes

Trial completed

Also in this update: Primary completion date changed from estimate of Oct 2026 to Jul 17, 2025; Final enrollment: 57 participants (planned 42)

University of AlbertaNot applicable NCT07009483 Registry history of NCT07009483 on ClinicalTrials.gov (opens the registry)

Updated Sep 23, 2026
Minor

Role of Confocal Microscopy in Estimating Dupilumab Treatment Response for Moderate/Severe Atopic Dermatitis

Trial completed

Also in this update: Primary completion date changed from estimate of Dec 12, 2025 to Apr 9, 2026

Hospital Italiano de Buenos AiresNot specified NCT07098000 Registry history of NCT07098000 on ClinicalTrials.gov (opens the registry)

Updated Sep 16, 2026
Minor

AQUA · Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Trial sites expanded: 150 → 154 locations

SanofiPhase 3 NCT06241118 Registry history of NCT06241118 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

Called PF-08049820 · Eczema

Trial sites expanded: 33 → 42 locations

And 1 more change in the last 30 days

PfizerPhase 2 NCT07216027 Registry history of NCT07216027 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

APG777 in Atopic Dermatitis

Trial sites expanded: 73 → 78 locations

Apogee Therapeutics, Inc.Phase 2 NCT07003425 Registry history of NCT07003425 on ClinicalTrials.gov (opens the registry)

Updated Oct 13, 2026
Minor

BROADEN2 · KT-621 Administered Orally to · Moderate to Severe Atopic Dermatitis

Trial sites reduced: 68 → 61 locations

Kymera Therapeutics, Inc.Phase 2 NCT07217015 Registry history of NCT07217015 on ClinicalTrials.gov (opens the registry)

Updated Oct 6, 2026
Minor

PossibILity · Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study · Atopic Dermatitis

Trial sites reduced: 68 → 59 locations

And 1 more change in the last 30 days

UCB Biopharma SRLPhase 2 NCT07277660 Registry history of NCT07277660 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

AURA-AD · REGN20423 in Healthy Adult Participants and Adult · Atopic Dermatitis

Trial sites expanded: 1 → 5 locations

Regeneron PharmaceuticalsPhase 1 NCT07527923 Registry history of NCT07527923 on ClinicalTrials.gov (opens the registry)

Updated Sep 25, 2026
Minor

ARMADA-AD · This Study is a Non-interventional Disease Registry of Adolescent and Adult · Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

Trial sites expanded: 79 → 82 locations

SanofiNot specified NCT07290803 Registry history of NCT07290803 on ClinicalTrials.gov (opens the registry)

Updated Sep 29, 2026
Minor

PROSE · Patients Receiving DUPIXENT® for Atopic Dermatitis (AD)

Study completion pushed from Mar 30, 2027 to Jul 28, 2027

Regeneron PharmaceuticalsNot specified NCT03428646 Registry history of NCT03428646 on ClinicalTrials.gov (opens the registry)

Updated Oct 9, 2026
Minor
2 trials marked Unknown by the registry's verification sweep
1. Minor
  
  LaCE (Lactobacillus Paracasei LPB27 On Early Childhood Eczema)
  
  Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
  
  The University of New South WalesPhase 2 NCT06584552 Registry history of NCT06584552 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
2. Minor
  
  Patient with Atopic Dermatitis' Needs for Self-management Support - Flexible Patient Centred Consultations
  
  Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
  
  University Hospital, Gentofte, CopenhagenNot applicable NCT06032403 Registry history of NCT06032403 on ClinicalTrials.gov (opens the registry)
  
  Changed Oct 4, 2026
Registry verification sweep

Changed Oct 4, 2026

Stopped: an ongoing trial was terminated, suspended or withdrawn.
Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
Minor: routine progress and housekeeping, such as sites added or enrollment closed.

First posted	Trial	Sponsor	Phase
2026-10-09	NCT07867249 Efficacy and Safety of Cream Containing Fig Extract in Subacute and Chronic Eczematous…	Chulalongkorn University new
2026-10-02	NCT07856134 AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of…	Forefront Dermatology S.C new	Phase 4
2026-09-29	NCT07846813 Evidencing Vibroacoustic Sensing for Inflammatory Skin Disease Monitoring	University of Edinburgh new
2026-09-25	NCT07842900 Oral Melatonin as Adjunctive Therapy in Adults With Atopic Dermatitis	Can Tho University of Medicine and Pharmacy new
2026-09-10	NCT07813611 Secondary Bacterial Infections and Nasal Colonization in Scabies and Atopic Dermatitis	Istanbul Medeniyet University new
2026-09-09	NCT07810777 PRA-216 Atopic Dermatitis Safety and Efficacy Study	Prana Therapies Inc new	Phase 2
2026-09-04	NCT07804134 Skin-in-Sight: a Longitudinal Cohort Infrastructure for Standardized Remote Monitoring…	Medisch Spectrum Twente new
2026-09-02	NCT07800104 Phase 1 Study of QX-4533 in Healthy Volunteers and Patients With Moderate-to-Severe…	QuantX Biosciences, Inc. new	Phase 1
2026-08-10	NCT07754968 Use of Bifidobacterium Bifidum in Formula-Fed Infants With Colic, With or Without Atopic…	University of Roma La Sapienza new
2026-08-05	NCT07746817 A Study of BYN-001 in Healthy Adults and in Adults With Moderate to Severe Atopic…	Bionyra Pharma new	Phase 1

NCT ID	Title	Sponsor	Status	Updated
Phase 4
NCT07447063	The Impact of Dietary Salt on the Severity of Eczema	University of California, San Francisco	Recruiting	2026-09-10
NCT07487831	The Impact of Salt Intake on Sodium in the Skin and Inflammatory Skin Disease	University of California, San Francisco	Recruiting	2026-09-09
NCT07560618	Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over…	Integrative Skin Science and Research	Recruiting	2026-08-13
NCT05858619	Molecular Signatures of Cutaneous Dupilumab Response	University of California, San Francisco	Recruiting	2026-06-04
NCT05042258	Using Dupilumab to Improve Circadian Function, Sleep and Pruritus in Children With…	Northwestern University	Recruiting	2026-04-27
NCT06116526	Dupilumab De-escalation in Pediatric Atopic Dermatitis	Johns Hopkins University	Recruiting	2026-04-20
NCT05268107	Ethnic Differences in Mechanisms of Action of Dupilumab	University of Michigan	Recruiting	2025-11-06
NCT06004986	DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Recruiting	2025-10-08
NCT05758532	Non-specific Effects of a Modified Measles Vaccination Schedule to Prevent Allergy and…	Laure Pittet, MD-PhD	Recruiting	2024-05-29
NCT05285839	Dupixent and Narrowband UVB for Atopic Dermatitis	Psoriasis Treatment Center of Central New Jersey	Recruiting	2024-03-15
NCT07856134	AD Treatment Optimization With Ebglyss in Real-World Practice: A Multicenter Study of…	Forefront Dermatology S.C	Not Yet Recruiting	2026-10-02
NCT07848074	Abrocitinib Dose Tapering in Patients With Atopic Dermatitis	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	Not Yet Recruiting	2026-09-29
NCT06906497	Lebrikizumab in Moderate-to-severe Atopic Dermatitis	Johann E Gudjonsson MD PhD	Active, Not Recruiting	2026-09-15
NCT07661979	Opzelura Experience Study	Wake Forest University Health Sciences	Not Yet Recruiting	2026-09-04
NCT07713186	Azithromycin in Atopic Dermatitis	Cairo University	Not Yet Recruiting	2026-07-20
NCT07352566	Utilization of a Microdevice for Psoriasis and Atopic Dermatitis	University of California, San Francisco	Not Yet Recruiting	2026-06-03
NCT05983068	A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric…	Sanofi	Active, Not Recruiting	2026-04-13
NCT06397781	Effect of S. Aureus Skin Decolonization on Disease Severity in Atopic Dermatitis Patients	Boston Children's Hospital	Not Yet Recruiting	2026-03-10
NCT07438509	Efficacy of Crisaborole 2% Cream Versus Placebo in Mild to Moderate Atopic Eczema	Jinnah Postgraduate Medical Centre	Not Yet Recruiting	2026-03-06
NCT05566262	Bodewell Products for the Treatment of Atopic Dermatitis	University of Alabama at Birmingham	Active, Not Recruiting	2026-03-02
NCT07437534	Comparative Evaluation of the Safety and Effectiveness of Crisaborole Ointment (2%)…	Hayat Abad Medical Complex, Peshawar	Not Yet Recruiting	2026-03-02
NCT07367932	Comparative Study of Crisaborole vs. Tacrolimus in Atopic Dermatitis	Cairo University	Not Yet Recruiting	2026-01-26
Phase 3
NCT07386743	A Phase III Study of GS101 Injection to Dupixent®	Jiangsu Genscend Biopharmaceutical Co., Ltd	Recruiting	2026-10-15
NCT07754786	A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants…	Innovent Biologics (Suzhou) Co. Ltd.	Recruiting	2026-10-15
NCT07765888	A Study to Learn About the Study Medicine Called Tilrekimig in People With…	Pfizer	Recruiting	2026-10-15

Early Phase 1		1
Phase 1		30
Phase 1/2		5
Phase 2		64
Phase 2/3		5
Phase 3		53
Phase 4		22

Atopic Dermatitis clinical trials

What changed in the last 30 days

New sponsor entrants, last 90 days sponsors with their first trial in this area

Active trials by phase

Active trials top 25 of 342

Top sponsors by active trials in this area